Biofunctionalized Gold Nanoparticles for Colorimetric Sensing of Botulinum Neurotoxin A Light Chain

Liu, Xiaohu; Wang, Yi; Chen, Peng; Wang, Yusong; Zhang, Jinling; Aili, Daniel; Liedberg, Bo

2014

Liu, X., Wang, Y., Chen, P., Wang, Y., Zhang, J., Aili, D., et al. (2014). Biofunctionalized Gold Nanoparticles for Colorimetric Sensing of Botulinum Neurotoxin A Light Chain. *Analytical Chemistry*, 86(5), 2345-2352.

<https://hdl.handle.net/10356/81846>

<https://doi.org/10.1021/ac402626g>

© 2014 American Chemical Society. This is the author created version of a work that has been peer reviewed and accepted for publication by *Analytical Chemistry*, American Chemical Society. It incorporates referee's comments but changes resulting from the publishing process, such as copyediting, structural formatting, may not be reflected in this document. The published version is available at: [<http://dx.doi.org/10.1021/ac402626g>].

Downloaded on 26 Apr 2023 10:43:06 SGT

Bio-functionalized Gold Nanoparticles for Colorimetric Sensing of Botulinum Neurotoxin A Light Chain

Xiaohu Liu, Yi Wang, Peng Chen, Yusong Wang, Jinling Zhang, Daniel Aili[†] and Bo Liedberg**

Centre for Biomimetic Sensor Science, Nanyang Technological University, 50 Nanyang Avenue,
637553 Singapore.

ABSTRACT: Botulinum neurotoxin is considered as one of the most toxic food-borne substances and is a potential bio-weapon accessible to terrorists. The development of an accurate, convenient and rapid assay for botulinum neurotoxins is therefore highly desirable for addressing biosafety concerns. Herein, novel biotinylated peptide substrates designed to mimic synaptosomal-associated protein 25 (SNAP-25) are utilized in gold nanoparticle-based assays for colorimetric detection of botulinum neurotoxin serotype A light chain (BoLcA). In these proteolytic assays, biotinylated peptides serve as triggers for the aggregation of gold nanoparticles, while the cleavage of these peptides by BoLcA prevents nanoparticle aggregation. Two different assay strategies are described, demonstrating limit of detection ranging from 5 nM to 0.1 nM of BoLcA with an overall assay time of 4 hours. These hybrid enzyme-responsive nanomaterials provide rapid and sensitive detection for one of the most toxic substances known to man.

Botulinum neurotoxins (BoNTs) are produced by *Clostridium botulinum* and are classified into seven serotypes designated from A to G,¹ each of which comprises a 100 kDa heavy chain (HC) and a 50 kDa light chain (LC) linked *via* a disulfide bond. The HC contains a binding domain and a translocation domain, whereas the LC possesses a catalytic domain responsible for the proteolytic function.² The HC is generally considered as a transport vehicle that specifically targets the axon termini *via* the binding domain and enters the neurons through receptor-mediated endocytosis.³ The translocation domain of HC mediates the escape of the LC from the endocytic vesicle to the cytoplasm.⁴ The LC proteolytically degrades components of SNARE (soluble N-ethylmaleimide-sensitive-factor attachment protein receptor) proteins, which prevents neurotransmitters from being released into the synaptic gap of the neuromuscular junctions. As a consequence, the subsequent muscle suffers from flaccid paralysis.⁵ BoNT therefore causes a serious and life-threatening illness (botulism).¹ It is considered as one of the most neuro-toxic substance known with an estimated lethal dose of 1.3-13 ng/kg, depending on the different ways of exposure, such as injection and inhalation.⁶ In addition of being a food pathogen, BoNT is also a potential bioterror weapon.⁷ Hence, there is a great need of accurate and rapid assays for botulinum neurotoxins.

Currently the standard method for detection of BoNT is the mouse bioassay in which the symptoms of botulism are observed 2-4 days after the animals have been injected with a BoNT containing sample.⁸ Alternative methods for BoNT detection include immunoassays.⁸ Although these assays have demonstrated very low limit of detections (LODs), in sub-picomolar range, they tend to be slow, labor intensive and provide little, if any, information about the enzymatic activity of BoNT.

By rational design of peptides containing a BoNT cleavage site it is possible to obtain substrates specific for each serotype LC of BoNTs as each of them has very specific recognition sequence.⁹ Those peptide-based BoNT substrates have been used in combination with mass spectroscopy, surface plasmon resonance, as well as Förster resonance energy transfer and electrochemical luminescence for monitoring the activity and concentration of BoNT.^{8,10-13} Unfortunately, most of these methods require highly advanced and expensive equipments.

Gold nanoparticles (AuNPs) have been extensively employed in bioanalytical applications. Different sizes and geometries of AuNPs, functionalized by proteins, peptides and oligonucleotides, enable novel sensing strategies for highly sensitive and robust detections of biomolecules and bio-molecular interactions.¹⁴⁻¹⁶ The optical properties of AuNPs offer possibilities to transduce molecular interactions into readily detectable colorimetric signals that can be recorded by standard laboratory equipment and sometimes even by the naked eye.¹⁷ The excitation of collective electron oscillations on the nanoparticle surface gives rise to a very pronounced extinction band in the visible wavelength regime. This localized surface plasmon resonance (LSPR) band is sensitive to local changes in refractive index and the aggregation/dispersion state of the nanoparticles. Particle aggregation typically results in a distinct red-shift of the LSPR band. Recently, peptide-functionalized AuNPs have been utilized for colorimetric sensing of metal ions,¹⁸⁻¹⁹ proteins,²⁰⁻²² and toxins.²³⁻²⁶ Designed peptides are excellent candidates as synthetic receptors because they are more robust than proteins (*e.g.* antibodies) and provide an enormous flexibility and versatility with respect to structural and chemical properties. Moreover, peptides are generally much smaller than proteins, which when used in combination with AuNPs results in smaller particle separation upon particle aggregation and thus a more pronounced optical shift.¹⁷

In this paper a rapid and robust colorimetric assay for BoNT serotype A light chain (BoLcA) is demonstrated. For peptides containing a BoLcA recognition/cleavage site, the proteolytic digestion by BoLcA drastically alters the aggregation pattern of the particles, which enables the concentration of active BoLcA to be determined. Two different assay strategies have been developed, using two different peptide-designs, Figure 1. Peptide **1** includes an anchor (thiol group), a spacer (PEG), the recognition/cleavage site (peptide itself), and a terminal biotin. Peptide **2**, on the other hand, has the recognition/cleavage site inserted between two biotins. In Strategy A (Mixing Assay), AuNPs are functionalized with the designed biotinylated-peptides (**1**-AuNPs) that aggregate with neutravidin functionalized AuNPs (navi-AuNPs). In Strategy B (Bridging Assay), aggregation of navi-AuNPs is induced by a bridging of the nanoparticles using the bi-biotinylated peptide **2**. These assays demonstrate LODs ranging from 5 nM (A) down to 0.1 nM (B) of BoLcA.

Figure 1. Schematic illustration of the mixing (A) and bridging (B) assays for detection of BoLcA using two peptide-designs (**1** and **2**) and bio-functionalized AuNPs.

EXPERIMENTAL SECTION

Materials. The modified peptide substrates Cys-PEG₁₁-SNKTRIDEANQRATKNorL-biotin (**1**) and biotin-KTRIDEANQRATK(biotin)Nor (**2**) were purchased from the Peptide Synthesis Core Facility, School of Biological Sciences, Nanyang Technological University, Singapore. The peptides were synthesized on the solid phase, identified using matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF) mass spectrometry and purified by HPLC. Botulinum neurotoxin serotype A light chain (BoLcA), SNAPtide[®] and unquenched calibration peptide for SNAPtide[®] were purchased from List Biological Labs, Inc. USA. PEG₇ thiol acid (O-(2-Carboxyethyl)-O'-(2-mercaptoethyl)-heptaethylene glycol) was purchased from Polypure AS, Norway. Neutravidin was purchased from Thermo Fisher Scientific Inc. USA. Other chemicals were purchased from Sigma-Aldrich without further notifications. Gold nanoparticles with an approximate average diameter of 20 nm were prepared by citrate reduction of HAuCl₄. Briefly, 12 mL HAuCl₄ (2.54 mM) was added to 102 mL pure water (MilliQ, 18.2 MΩ cm) under stirring and brought to boil in a round-bottom flask with a condenser to maintain a constant volume of the reaction mixture. Upon boiling, 6 mL of 10 mg/mL sodium citrate was added and continued boiling for another 30 minutes under stirring until the solution turned to red color. Gold nanoparticles with an approximate average diameter of 28 nm were synthesized by the same method with a lower reaction temperature (60 °C).

Peptide functionalization of AuNPs (1-AuNP). PEG₇ thiol acid (aPEG) was mixed with the peptide substrate (**1**) at different concentration ratios ranging from 0.004 to 0.02 (**1**:aPEG) in 500 μL of 50 mM HEPES [4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid] buffer (pH 7.4, 0.05% Tween 20) followed by addition of an equivalent volume of 20 nm AuNPs (0.5 nM) and incubated for 2 hours. The final concentration of the aPEG molecules was 25 μM. The AuNPs

were repeatedly centrifuged and resuspended in fresh 50 mM HEPES buffer until estimated free peptide concentration in the solution was less than 1 pM. The purified AuNPs were concentrated to 5 nM and stored at 4 °C until use.

Neutravidin functionalization of AuNPs (navi-AuNPs). AuNPs (20 nm and 28 nm) were modified with neutravidin by incubation 500 μ L of AuNPs (0.5 nM and 0.18 nM, respectively) with 100 μ L of 1 mg/mL neutravidin in 400 μ L of 20 mM carbonate buffer (pH 10) for 2 hours. Unbound neutravidin was removed by repeated centrifugations and particles were resuspended in fresh carbonate buffer (pH 10) until the estimated concentration of free neutravidin in solution was less than 1 pM. Finally, the neutravidin modified AuNPs were resuspended in 50 mM HEPES buffer.

Mass spectrometry. BoLcA was added into the synthetic peptides solution in 50 mM HEPES buffer pH 7.4 with 0.05% Tween 20, to achieve final concentrations of 20 nM BoLcA and 10 μ M peptide substrates, followed by incubation at 37 °C for 3 hours. The enzymatic reaction was terminated by heating to 80 °C. The reaction solution was desalted using reversed phase ZipTip (Merck Millipore, Germany) prior to analysis by MALDI-TOF mass spectrometry.

Analysis of BoLcA proteolytic activity with SNAPtide[®]. For the calibration analysis, freshly prepared 1 μ M solution of unquenched calibration peptide in 50 mM HEPES buffer was further diluted into appropriate wells of 96-well plate (Corning) to make the final amount from (0 to 0.2 nmoles). For the SNAPtide[®] cleavage assay, 0.5 nmoles of SNAPtide[®] in 50mM HEPES buffer was added into wells and reactions started by adding 8.3 nM of BoLcA at 37 °C. The data from the calibration and cleavage assays were collected using a Tecan Infinite M200 Pro Plate Reader (Tecan, Research Triangle Park, NC) in the kinetic mode in which the excitation and emission wavelength were set as 490 nm and 523 nm, respectively.

Detection of BoLcA by colorimetric gold nanoparticle assays. In mixing assay (Figure 1A), various concentrations of BoLcA spiked in HEPES buffer were incubated with 10 μ L of **1**-AuNPs (5 nM) at 37 °C for 20 hours. The reaction was terminated by heating to 80 °C and the solution was diluted 10 times with 50 mM HEPES buffer. UV-visible (UV-vis) spectra were recorded immediately after mixing the reacted **1**-AuNPs and navi-AuNPs (100 μ L of each, 20 nm, 0.25 nM) with 2-minute intervals for 90 minutes. Negative control (aPEG-AuNPs) and blank control (**1**-AuNPs without BoLcA pre-incubation) were performed in the same way. In order to test the influence of immobilization of **1** on the accessibility of BoLcA to hydrolyze **1**, various concentrations of **1** (0.1 - 10 μ M) was incubated with BoLcA prior to immobilization on AuNPs. Subsequently, the BoLcA treated **1**-AuNPs were mixed with navi-AuNPs in the same way as above. UV-vis spectra were obtained after 90 minutes. In the peptide bridging assay (Figure 1B), **2** was incubated with various concentrations of BoLcA in HEPES buffer at 37 °C for 3 hours followed by addition of purified navi-AuNPs (28 nm, 0.18 nM). UV-vis spectra were recorded immediately after mixing with 2-minute intervals for 30 minutes.

RESULTS AND DISCUSSION

Peptide design. Intensive work has been carried out in order to reveal the substrate requirements for BoNT serotype A (BoNT/A).²⁷⁻²⁸ It has been found that a short peptide derived from the C-terminal end (187-203) of the SNAP-25 protein can be hydrolyzed by BoNT at a similar rate as the full length SNAP-25, as long as the peptide has a minimum length of 14 to 16 amino acids (*i.e.* 9 to 11 residues on the carboxyl-terminal side of the cleaving amide bond and 5 on the amino-terminal side) and the P1' site of arginine is retained.²⁸ Extensive interactions (*e.g.* hydrophobic side-chain interactions, polar side-chain and backbone contacts) between the short

peptide substrate and BoLcA have been confirmed.²⁹ Notably, a β -exosite present at the C-terminus of the peptide substrate has been reported to significantly improve both the substrate-enzyme binding affinity and the catalytic rate.²⁹ The β -exosite is separated from the cleavage site by 2 residues and forms a β -sheet together with the '250 loop', which is a region encompassing residue 242-259 of BoLcA.

With this in mind, two synthetic peptide substrates were designed (**1** and **2**). The sequence of peptide **1** is based on the 17 amino acids at the C-terminus of SNAP-25 protein (187-203) as indicated in Figure 1A, but with methionine (M) in position 202 replaced by norleucine (Nor). The substitution of M with Nor previously has been found to increase the proteolytic rate of BoLcA.²⁷ At the same time it prevents the potentially problematic interaction between the AuNPs and the sulphur-containing side chain of methionine. This 17-amino acid peptide contains all the BoLcA recognizing residues that are close to the cleavage site including a β -exosite at the C-terminus. The amide bond between glutamine and arginine (Q-R) located in the middle of the target peptide is the cleavage point for BoLcA proteolysis, as indicated in Figure 1. The proteolytic cleavage of **1** by BoLcA at this position was confirmed using MALDI-TOF. After 3-hour incubation of **1** with BoLcA at 37 °C, two peaks appeared corresponding to the N-terminal half of **1** ($m/z = 1977$) and the C-terminal half ($m/z = 1055$) (Supporting Information, Figure S-1).

Peptide **1** was designed to be immobilized directly on AuNPs *via* a thiol moiety at the N-terminal Cys residue. The BoLcA recognition sequence was separated from the Cys residue by an 11-unit ethylene glycol oligomer in order to minimize steric hindrance caused by immobilization to the AuNPs. A biotin-group was attached to the C-terminal in order to enable specific aggregation when exposed to neutravidin functionalized AuNPs (navi-AuNPs).

Peptide **2** (Figure 1B) shared 14 of the core amino acids of **1** but was modified with two biotin moieties, one at each terminus. The two biotins were incorporated to facilitate specific supramolecular cross-linking of navi-AuNPs.

Surface functionalization of gold nanoparticles. In order to increase the colloidal stability of the peptide-modified AuNPs and to allow tuning of the peptide surface concentration, **1** was co-immobilized with PEG₇ thiol acid (aPEG). Solutions with various molar ratios of **1** and aPEG (**1**:aPEG) ranging from 0.004 to 0.02 were investigated. The UV-vis spectra showed a minor peak-shift of the LSPR band from 520 nm to 522 nm (Figure 2a). The surface functionalization of the AuNPs with the thiolated molecules was expected to result in a mixed monolayer of **1**:aPEG with an approximate film thickness of 4 nm, which was confirmed by the observed 2 nm shift ($\Delta\lambda$) of the LSPR band. Calculations based on the model reported by Read et al.³⁰ using a penetration depth $l_p = 20$ nm and $n = 1.45$ yielded $\Delta\lambda = 1.8$ nm, which was in good agreement with the experimental observations (For a brief introduction to the method proposed by Read et al. see Supporting Information, Text S-1). The modified particles, **1**-AuNPs, were highly stable at molar ratios of **1**:aPEG < 0.02. The number of immobilized peptides per nanoparticle was estimated based on the assumption that the binding affinities of **1** and aPEG to the gold particles ($d = 20$ nm) were equal and that each molecule would occupy a surface area of 0.2 nm^2 . Accordingly, the number of **1** on each AuNP at a ratio **1**:aPEG = 0.01 was about 63 peptides (Supporting Information, Table S-1).

The 20 nm AuNPs showed a 5 nm red-shift of the LSPR band after functionalization with neutravidin (Figure 2b), because of the increase in refractive index upon protein adsorption. Furthermore, an increase in particle size from 20 nm (size of the citrate stabilized AuNPs) to an average of 26 nm in diameter after the modification with neutravidin was observed using

dynamic light scattering (Supporting information, Figure S-2). These results are reasonable since the 60 kDa neutravidin is a globular protein with a diameter around 3-4 nm. Neutravidin has an isoelectric point (pI) of 6.3 and the adsorption was carried out at pH 10 to prevent unspecific charge induced bridging aggregation of the citrate capped AuNPs. The adsorption of neutravidin to gold was facilitated by both hydrophobic interactions and formation of covalent bonds by thiol groups present in Cys residues on the protein surface.³¹

Figure 2. (a) Normalized extinction spectra of AuNPs (red) and **1**-AuNPs (blue). Inset: zoom-in of the LSPR peak-shift. (b) Normalized extinction spectra of AuNPs (red) and navi-AuNPs (blue).

Colorimetric particle-mixing assays of BoLcA. AuNPs modified with only aPEG (aPEG-AuNPs) demonstrated excellent colloidal stability. Incubating aPEG-AuNPs with navi-AuNPs did not induce any detectable changes in the LSPR-band, indicating that no significant attractive interactions exist between the aPEG-AuNPs and navi-AuNPs. However, the **1**-AuNPs showed more than 20 nm red-shift of the LSPR band after addition of navi-AuNPs, resulting in a partial precipitation (Supporting Information, Figure S-3). The presence of the biotinylated peptide **1** on the AuNPs was thus critical for inducing particle aggregation. The LSPR shift was saturated within 1-2 hours, which was slower than the kinetics of the biotin-neutravidin interaction in

solution.³² This could be ascribed to the slow diffusion and relatively low collision frequency of the AuNPs as well as the accessibility of the biotin moiety to the immobilized neutravidin. In the mixing assay, the peptide-modified particles were first incubated with BoLcA (Direct assay), before addition of navi-AuNPs. After a 20 hours incubation of **1**-AuNPs (**1**:aPEG = 0.01) with 100 nM BoLcA, no shift of the LSPR peak was obtained upon addition of navi-AuNPs (Figure 3a). In addition, transmission electron microscope (TEM) images primarily showed dispersed particles (Supporting Information, Figure S-4a), strongly suggesting that the proteolytic cleavage of **1** by BoLcA, excised the C-terminal biotin group in **1**, which prevented the specific association with navi-AuNPs. In contrast, a shift from 525 to 548 nm ($\Delta\lambda = 23\text{nm}$) was observed for the **1**-AuNPs not exposed to BoLcA prior to addition of navi-AuNPs (Figure 3b), which was confirmed by the presence of large particle aggregates in TEM image (Supporting Information, Figure S-4b). The dramatic difference in the LSPR band of **1**-AuNPs could be clearly observed by the naked eye (inset, Figure 3) as a pronounced difference in color with and without incubation of 100 nM BoLcA.

Figure 3. Normalized extinction spectra of the mixture solution of navi-AuNPs and **1**-AuNPs which was pre-incubated with (a) 100nM BoLcA and without (b) BoLcA (as control). Inset: photographs of AuNP solutions.

In order to optimize the sensor response, AuNPs were modified in solutions containing different molar ratios of **1** and aPEG ranging from 0.004 to 0.02. As shown in Figure 4a, the extent of the LSPR peak-shift after addition of navi-AuNPs ($\Delta\lambda_c$) increased when increasing the relative amount of **1**. Maximum aggregation was achieved at a molar ratio of **1**:aPEG > 0.01 (black line, Figure 4a). The optical shift when first exposing **1**-AuNPs to BoLcA ($\Delta\lambda_s$) varied for the different ratios of **1**:aPEG (100 nM BoLcA, 20 hours incubation). The sensor response ($\Delta\lambda_r$) is defined as the difference between the LSPR peak-shifts with and without BoLcA treatment, *i.e.* $\Delta\lambda_r = \Delta\lambda_c - \Delta\lambda_s$.

A very low response $\Delta\lambda_r$ was obtained for ratios of **1**:aPEG > 0.02 and < 0.004, whereas substantial responses were seen for **1**:aPEG ratios between 0.004 and 0.02, peaking at around 0.01 (broken blue line, Figure 4a). At a low surface concentration of **1**, the low number of biotins on each particle limited the probability for aggregation by navi-AuNPs. At a high surface concentration of **1** there was on the other hand extensive particle aggregation upon exposure to navi-AuNPs, as a large fraction of these peptides had to be hydrolyzed by BoLcA in order to produce a significant sensor response. Accordingly, the **1**:aPEG ratio of 0.01 was considered as optimal, providing a maximum sensor capacity and sensitivity for BoLcA detection. The sensor response for concentrations of BoLcA ranging from 1 nM to 100 nM is shown in Figure 4b. The LOD for the detection of BoLcA was estimated to be 5 nM, which was equal to the concentration of BoLcA at which the sensor response was 3 times to the standard deviation of the control experiments.

This strategy, however, suffered from a relatively long assay time, typically requiring 20 hours of incubation of **1**-AuNPs with the BoLcA sample in order to provide a large enough sensor response. Furthermore, it has been known that the active site of BoLcA is buried rather deep inside the protein (*ca.* 2.4nm).³³ Thus, steric constraints induced by the AuNP might affect the accessibility of BoLcA to the cleavage site of **1** although the peptide was attached to gold *via* a long oligo(ethylene glycol) spacer. The flexibility of the long spacer could potentially also allow for conformations/orientations of **1** that were unfavorable for hydrolysis.¹³ Additionally, the short peptide substrate might not be as efficiently recognized by BoLcA as the whole SNAP-25 protein,³⁴ and the N-terminal spacer group on **1** might reduce the specificity for catalytic cleavage of BoLcA. It should be stressed that the catalytic rate constant k_{cat} of BoLcA measured with the standard SNAPtide[®] was estimated as 22.6 per hour (Supporting Information, Figure S-5) which was significantly lower than previously reported,¹¹ indicating that the BoLcA utilized here did not display as high activity as other BoNT proteases.¹

In order to better understand the steric constraints caused by immobilization, peptide **1** was incubated with BoLcA prior to immobilization on the AuNPs (Indirect assay). 10 nM BoLcA was incubated with **1** (0.1 μ M - 10 μ M) for 3 hours prior to addition of citrate capped AuNPs (0.5 nM) and aPEG (**1**:aPEG = 0.003). The **1**-AuNPs were incubated for 2 hours and purified by repeated centrifugations. UV-vis spectra were subsequently obtained after 2 hours mixing of the **1**-AuNPs with the navi-AuNPs. Significantly more aggregation was observed without BoLcA treatment (Figure 4c). The sensor response $\Delta\lambda_r$ (broken blue line) showed a similar trend as the direct method described above, with a maximum response at 2 - 4 μ M of free **1**. An LOD of 0.4 nM BoLcA was obtained subsequently by using 3 μ M of peptide **1** (Figure 4d).

Figure 4. (a) Comparison of LSPR peak-shifts induced by different molar ratios of **1** and aPEG functionalized AuNPs after mixing with navi-AuNPs. Black squares: controls $\Delta\lambda_c$; Red circles: samples pre-incubated with 100nM BoLcA $\Delta\lambda_s$; Blue triangles: sensor response $\Delta\lambda_r$. (b) Calibration curve for the peak-shifts as a function of the BoLcA concentrations by the direct assay. (Error bars are the standard error of the mean, $n \geq 3$) (c) Comparison of LSPR peak-shifts induced by different concentrations of **1**. Black squares: controls $\Delta\lambda_c$; Red circles: **1** incubated with 10nM BoLcA for 3 hours prior to immobilization on AuNPs and addition of navi-AuNPs $\Delta\lambda_s$; Blue triangles: sensor response $\Delta\lambda_r$. (d) Calibration curve for the peak-shifts as a function of the BoLcA concentrations by the indirect assay. (Error bars are the standard error of the mean, $n \geq 3$)

Despite using a significantly shorter incubation time (3 hours), the 10-fold higher sensitivity obtained when exposing **1** to BoLcA prior to immobilization highlighted the strong negative influence of immobilization on the accessibility of the peptide to enzymatic hydrolysis.

The activity of BoLcA on free **1** was estimated under the assumption that un-cleaved **1** would induce AuNPs aggregation accordingly. Figure 4c showed 0.9 nm of peak-shift $\Delta\lambda_s$ at 2 μ M of **1** which was about 10% of the control peak-shift $\Delta\lambda_c = 8.5$ nm, indicating ~90% of **1** was proteolyzed by 10 nM BoLcA. Accordingly, the rate of cleavage k_{cat} was estimated as 69 ± 10 per hour, which was about 3-fold better than the standard SNAPtide[®] assay (Supporting Information, Figure S-5). This might be due to a longer recognition sequence of **1** and the better design of the sequence (for instance the replacement of M with Nor) as compared to SNAPtide.

Colorimetric peptide-bridging assay of BoLcA. In order to circumvent the problems imposed by the immobilization of **1**, a second peptide (**2**) was designed. Peptide **2** was incorporated with two biotin moieties (biotin-KTRIDEANQRATK(biotin)Nor), thus capable of bridging navi-AuNPs, unless hydrolyzed (Figure 1B). Addition of **2** to navi-AuNPs caused a concentration dependent red-shift of the LSPR band, saturating at about $\Delta\lambda_c=17.5$ nm for 75 nM of peptide **2** after 30 minutes incubation (Figure 5a). The sigmoidal shape of the response curve suggested a certain amount of unspecific interactions. If the aggregation were induced solely by the biotin-mediated binding, a bell-shape curve would be expected since neutravidin-binding sites would be saturated at high concentrations, preventing aggregation.

This was further confirmed by addition of the C-terminal half of **2** (**2'**C = RATK(biotin)Nor), that mimicked the C-terminal product after hydrolysis of **2** by BoLcA. Partial aggregation of navi-AuNPs was observed at high concentration of **2'**C (75 nM) as indicated in the peak-shift $\Delta\lambda_s = 7$ nm (red line, Figure 5a). This aggregation was presumably caused by the combination of

the biotin and the positive net-charge of **2**'C that could induce unspecific bridging aggregation of the slightly negatively charged navi-AuNPs (pI of navi is 6.3). The second product, *i.e.* the N-terminal of the peptide (**2**'N = Biotin-KTRIDEANQ) has a negative net-charge and thus showed no observable peak-shift upon incubation with navi-AuNPs. The aggregation of navi-AuNPs induced by **2** could therefore be due to both specific and a minor amount of unspecific interactions. The peak-shift difference $\Delta\lambda_r = \Delta\lambda_c - \Delta\lambda_s$ showed a maximum response at the peptide concentration of 50 nM (broken blue line, Figure 5a), which was the concentration used in further experiments for detection of BoLcA. An inverse relationship was found between the LSPR peak-shift and the amount of BoLcA upon addition of the pre-BoLcA-incubated **2** to navi-AuNPs. The concentration dependent peak-shift $\Delta\lambda_r$ and color changes are shown in Figure 5b and 5c, respectively. The LOD was found to be 0.1 nM (5 ng/mL of BoLcA), which is 50 times lower as compared to the direct assay based on peptide **1** (Supporting Information, Table S-2). This lower LOD is most likely the result of using a non-immobilized substrate in combination with a strategy where a relatively limited number of peptides had to be cleaved in order to affect the aggregation characteristics. Moreover, the bridging assay provided 3-fold better LOD than a previously reported quantum dot-based FRET method with LOD ~ 350 pM and assay time of 2-3 hours¹³ and comparable LOD as antibody-based SPR sandwich assay (LOD of 1 ng/mL and assay time of 1-2 hours)³⁵ but worse LOD as compared to mouse lethality assay (LOD of 20-30 pg/mL and assay time of 2-4 days),³⁶ antibody-based ELISA (LOD of 0.2-2 ng/mL and assay time of 4 hours),³⁷⁻³⁸ aptamer-based electrochemical assay (LOD of 40 pg/mL and assay time of 24 hours).³⁹ The LOD demonstrated here is estimated to 5 ng/mL for BoLcA (MW 50 kDa), which, upon assuming that the catalytic activity is the same for BoLcA and BoNT/A, corresponds to 15 ng/mL for the intact toxin BoNT/A (MW 150 kDa). Although the lethal dose

is not known for humans it can be estimated from investigations on primates. For a person with a body weight of 60 kg the lethal dose varies between 70 to 130 ng by injection (intravenously or intramuscularly), 600 to 800 ng (inhalationally) or 60 µg (orally).⁶ For oral intake, 60 µg of BoNT/A in a volume of 100 mL corresponds to 600 ng/mL that exceeds our LOD by a factor of 40. For a baby (5 kg), the corresponding calculation (in 100 mL) gives a lethal dose of about 50 ng/mL, which is still above our estimated LOD. For injection of 0.1 mL, which is the typical volume used in cosmetic applications, the concentration of BoNT/A is also around 700 ng/mL for a lethal dose of 70 ng. Thus, the LOD of our assay is below, and in some cases even well below the lethal concentrations of BoNT/A. It should also be noted that the bridging assay only requires one step after exposure to the sample resulting in a relatively short assay time of 4 hours.

We have in this manuscript compared two assays for detection of BoLcA, and discussed their respective pros and cons. Although, it is generally advisable to test new sensor technologies and assays under real conditions before making too far reaching conclusion about the overall performance, it is not within the scope of the current study to validate the assays in more complex environments. However, we are currently exploring strategies to test our assays in complex matrices by repeating the experiments in milk, honey, tap water and etc. We are also exploiting different assay formats and carriers for field applications, to be published separately.

There are indeed several obstacles to account for when employing aggregation assays based on AuNPs in complex solutions because of uncontrolled adsorption of unknown substances onto the surfaces of the AuNPs. The particles may aggregate due to a variety of reasons and cause false negatives. The AuNP surfaces may also be blocked by proteins thereby preventing the specific peptide(biotin)-neutravidin interactions to occur. The Bridging Assay using Peptide **2**, however,

offers an opportunity to reduce the above obstacles as it minimizes the exposure of the AuNPs to complex solutions. Moreover, the simplicity of the assays and the use of robust molecular components (peptides) offer an attractive route for production of cheap assays with long shelf-life for applications in field tests in resource limited countries.

Figure 5. (a) Comparison of LSPR peak-shifts induced by different concentrations of **2** (black squares) and **2'C** (red circles) incubated with navi-AuNPs. The blue triangles show the peak-shift differences $\Delta\lambda_r$ between the **2** and **2'C**. (b) Calibration curve for the peak-shifts as a function of the BoLcA concentrations by the bridging assay. (Error bars are the standard error of the mean, $n \geq 3$) (c) Photograph of the navi-AuNP solutions after mixing against **2** pre-incubated with 10, 3, 1, 0.3, 0.1 and 0 nM of BoLcA.

CONCLUSIONS

Peptides are attractive candidates for bio-molecular recognition instead of protein-based receptors (*e.g.* antibodies). They offer comparable selectivity, in combination with high robustness. As reported here, peptide substrates (**1** and **2**) were designed and successfully employed for the detection of BoLcA by using a colorimetric colloidal gold reporter system. Biotinylated peptides served as the trigger for the aggregation of AuNPs. The presence of BoLcA induced the cleavage of the biotin parting from the peptide thus keeping the AuNPs dispersed. In Strategy A, the surface-based direct detection method showed an LOD of 5 nM, while the solution-based indirect detection by pre-incubation of the free peptide with BoLcA prior to the functionalization of AuNPs provided an LOD of 0.4 nM (20 ng/mL). This LOD in combination with a short incubation time (3 hours) was comparable to many of other detection assays.^{8,13} Additionally, the steric constraints induced by the AuNPs could be eliminated by employing the indirect assay. However, one more step of sample preparation was required for this assay. In order to further reduce the assay time and simplify the procedure, Strategy B was performed. The bi-biotinylated peptide **2** was incubated with the BoLcA sample and subsequently mixed with the navi-AuNPs. This was a simple one-step process with a total assay time of 4 hours. The LOD of this method was 0.1 nM, that is 50-fold lower as compared to the direct mixing assay (A). The reproducibility of the assays reported herein can be considered as good based on the standard deviations for the experiments presented in Fig 4b, d and Fig 5b, given that they rely on experiments undertaken during a time span of several months.

The detection is actually reporting the activity rather than the amount of BoLcA, which is more valuable in sensing applications due to the crucial role played by the proteolytic function of botulinum neurotoxins. In addition, the specificity is ensured by employing peptides designed

specifically for BoLcA recognition and catalytic cleavage, based on the actual BoNT substrate.⁹ Importantly, here the particles aggregation state is inversely related to the activity of BoLcA. This inverse relation also effectively reduces the possibility of false positives. Taken together, the colorimetric detection method described herein provides an attractive alternative for the detection of other serotypes of botulinum neurotoxins, other types of proteolytic toxins, or even multi-detection by the modification of the peptide sequence.

The sensitivity and assay time can probably be improved by optimizing the peptide substrate to make it more accessible to the analyte. It is also possible to improve the sensitivity and LOD by varying the concentration of AuNPs. Experiments along this line have been explored for another system (Troponin I detection using peptide decorated spherical nanoparticles) and we observed that lowering the concentration of AuNPs offered a slightly improved LOD. However, the dynamic range was reduced upon lowering the concentration of AuNPs. Thus, there is a trade off between LOD and dynamic range that needs to be taken into account when optimizing the AuNP assays. Due to the minor improvement in LOD for the Troponin I system, we have not specifically studied the effect of different concentrations of AuNPs in the presently employed assay formats. Finally, we believe that the presented BoLcA detection strategies offer a good opportunity for the integration of colorimetric assays into a lateral flow device or a paper based format for point-of-care and field applications.

ASSOCIATED CONTENT

Supporting Information

Additional experimental details as described in the text. This material is available free of charge *via* the Internet at <http://pubs.acs.org>.

AUTHOR INFORMATION

Corresponding Authors

* Bo Liedberg: Tel: +65 6316 2957. Email: bliedberg@ntu.edu.sg

* Daniel Aili: Tel: +46 13 282616. E-mail: danai@ifm.liu.se

Present Address

† Division of Molecular Physics, Department of Physics, Chemistry and Biology, Linköping University, 58183 Linköping, Sweden.

Author Contributions

The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.

ACKNOWLEDGEMENT

This research is supported by Science & Engineering Research Council (SERC) of Agency for Science, Technology and Research (A*STAR), for projects under the numbers of 102 152 0015. D.A. also acknowledges support from the Swedish Research Council (VR), the Swedish Foundation for Strategic Research (SSF), the Knut and Alice Wallenberg Foundation (KAW) and the Centre in Nano science and technology (CeNano).

REFERENCES

- (1) Montecucco, C.; Molgo, J. *Curr. Opin. Pharmacol.* **2005**, *5*, 274-279.
- (2) Singh, B. R. *Neurotox. Res.* **2006**, *9*, 73-92.
- (3) Schiavo, G.; Matteoli, M.; Montecucco, C. *Physiol. Rev.* **2000**, *80*, 717-766.
- (4) Li, L.; Singh, B. R. *J. Toxicol. Toxin Rev.* **1999**, *18*, 95-112.

- (5) Foran, P. G.; Mohammed, N.; Lisk, G. O.; Nagwaney, S.; Lawrence, G. W.; Johnson, E.; Smith, L.; Aoki, K. R.; Dolly, J. O. *J. Biol. Chem.* **2003**, 278, 1363-1371.
- (6) Arnon, S. S.; Schechter, R.; Inglesby, T. V.; Henderson, D. A.; Bartlett, J. G.; Ascher, M. S.; Eitzen, E.; Fine, A. D.; Hauer, J.; Layton, M.; Lillibridge, S.; Osterholm, M. T.; O'Toole, T.; Parker, G.; Perl, T. M.; Russell, P. K.; Swerdlow, D. L.; Tonat, K.; Biodefense, W. G. C. *Jama-J. Am. Med. Assoc.* **2001**, 285, 1059-1070.
- (7) Koirala, J.; Basnet, S. *Infect. Med.* **2004**, 21, 284-+.
- (8) Cai, S.; Singh, B. R.; Sharma, S. *Crit. Rev. Microbiol.* **2007**, 33, 109-125.
- (9) Turton, K.; Chaddock, J. A.; Acharya, K. R. *Trends Biochem. Sci.* **2002**, 27, 552-558.
- (10) Kalb, S. R.; Smith, T. J.; Moura, H.; Hill, K.; Lou, J. L.; Geren, I. N.; Garcia-Rodriguez, C.; Marks, J. D.; Smith, L. A.; Pirkle, J. L.; Barr, J. R. *Int. J. Mass Spectrom.* **2008**, 278, 101-108.
- (11) Schmidt, J. J.; Stafford, R. G. *Appl. Environ. Microbiol.* **2003**, 69, 297-303.
- (12) Marconi, S.; Ferracci, G.; Berthomieu, M.; Kozaki, S.; Miquelis, R.; Boucraut, J.; Michael, S. B.; Leveque, C. *Toxicol. Appl. Pharmacol.* **2008**, 233, 439-446.
- (13) Sapsford, K. E.; Granek, J.; Deschamps, J. R.; Boeneman, K.; Blanco-Canosa, J. B.; Dawson, P. E.; Susumu, K.; Stewart, M. H.; Medintz, I. L. *ACS Nano* **2011**, 5, 2687-2699.
- (14) Ghadiali, J. E.; Stevens, M. M. *Adv. Mater.* **2008**, 20, 4359-4363.
- (15) Rosi, N. L.; Mirkin, C. A. *Chem. Rev.* **2005**, 105, 1547-62.
- (16) Wilson, R. *Chem. Soc. Rev.* **2008**, 37, 2028-45.
- (17) Aili, D.; Stevens, M. M. *Chem. Soc. Rev.* **2010**, 39, 3358-3370.
- (18) Aili, D.; Enander, K.; Rydberg, J.; Nesterenko, I.; Bjorefors, F.; Baltzer, L.; Liedberg, B. *J. Am. Chem. Soc.* **2008**, 130, 5780-5788.
- (19) Slocik, J. M.; Zabinski, J. S.; Phillips, D. M.; Naik, R. R. *Small* **2008**, 4, 548-551.

- (20) Aili, D.; Mager, M.; Roche, D.; Stevens, M. M. *Nano Lett.* **2011**, *11*, 1401-1405.
- (21) Aili, D.; Selegard, R.; Baltzer, L.; Enander, K.; Liedberg, B. *Small* **2009**, *5*, 2445-52.
- (22) Chen, P.; Selegård, R.; Aili, D.; Liedberg, B. *Nanoscale* **2013**, DOI:10.1039/C3NR03006G.
- (23) Laromaine, A.; Koh, L. L.; Murugesan, M.; Ulijn, R. V.; Stevens, M. M. *J Am Chem Soc* **2007**, *129*, 4156-+.
- (24) Wang, Z.; Levy, R.; Fernig, D. G.; Brust, M. *J Am Chem Soc* **2006**, *128*, 2214-5.
- (25) Guarise, C.; Pasquato, L.; De Filippis, V.; Scrimin, P. *Proc Natl Acad Sci U S A* **2006**, *103*, 3978-82.
- (26) Gupta, S.; Andresen, H.; Ghadiali, J. E.; Stevens, M. M. *Small* **2010**, *6*, 1509-13.
- (27) Schmidt, J. J.; Bostian, K. A. *Journal of Protein Chemistry* **1995**, *14*, 703-8.
- (28) Schmidt, J. J.; Bostian, K. A. *Journal of Protein Chemistry* **1997**, *16*, 19-26.
- (29) Blasi, J.; Chapman, E. R.; Link, E.; Binz, T.; Yamasaki, S.; Decamilli, P.; Sudhof, T. C.; Niemann, H.; Jahn, R. *Nature* **1993**, *365*, 160-163.
- (30) Read, T.; Olkhov, R. V.; Shaw, A. M. *Phys. Chem. Chem. Phys.* **2013**, *15*, 6122-7.
- (31) Hermanson, G. T. *Bioconjugate Techniques*, 2nd ed.; Academic Press, 2008.
- (32) Marttila, A. T.; Laitinen, O. H.; Airenne, K. J.; Kulik, T.; Bayer, E. A.; Wilchek, M.; Kulomaa, M. S. *FEBS Lett* **2000**, *467*, 31-6.
- (33) Kukreja, R.; Singh, B. R. In *Microbial Toxins: Current Research and Future Trends*; Caister Academic Press., 2009.
- (34) Breidenbach, M. A.; Brunger, A. T. *Nature* **2004**, *432*, 925-929.
- (35) Ladd, J.; Taylor, A. D.; Homola, J.; Jiang, S. Y. *Sensors and Actuators B: Chemical* **2008**, *130*, 129-134.
- (36) Lindstrom, M.; Korkeala, H. *Clin Microbiol Rev* **2006**, *19*, 298-+.

(37) Poli, M. A.; Rivera, V. R.; Neal, D. *Toxicon* **2002**, 40, 797-802.

(38) Szilagyi, M.; Rivera, V. R.; Neal, D.; Merrill, G. A.; Poli, M. A. *Toxicon* **2000**, 38, 381-389.

(39) Wei, F.; Ho, C. M. *Anal Bioanal Chem* **2009**, 393, 1943-1948.

For Table of Contents Only